Literature DB >> 2291864

Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?

T Pullar1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291864      PMCID: PMC1368239          DOI: 10.1111/j.1365-2125.1990.tb03807.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  59 in total

1.  Combined therapy of rheumatoid arthritis with gold and chloroquine. I. Evaluation of the therapeutic effect.

Authors:  K SIEVERS; L HURRI
Journal:  Acta Rheumatol Scand       Date:  1963

2.  Chloroquine and rheumatoid arthritis; a short-term controlled trial.

Authors:  A FREEDMAN
Journal:  Ann Rheum Dis       Date:  1956-09       Impact factor: 19.103

3.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

4.  Can we develop simple response criteria for slow acting antirheumatic drugs?

Authors:  D L Scott; J E Dacre; A Greenwood; L Treasure; E C Huskisson
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

5.  Non-steroidal analgesic and anti-inflammatory agents.

Authors:  G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

6.  Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR, and clinical response.

Authors:  M G Grimaldi
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

7.  Does second-line therapy affect the radiological progression of rheumatoid arthritis?

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

8.  Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br J Rheumatol       Date:  1985-08

9.  Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.

Authors:  G Borg; E Allander; B Lund; E Berg; U Brodin; H Pettersson; L Trang
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

10.  A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis.

Authors:  H A Bird; J Hill; N G Sitton; J S Dixon; V Wright
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

View more
  4 in total

Review 1.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 2.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

3.  Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects.

Authors:  J Ducharme; H Fieger; M P Ducharme; S K Khalil; I W Wainer
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

4.  Effects of stanozolol on normal and IL-1β-stimulated equine chondrocytes in vitro.

Authors:  Mariana Castro Martins; Mandy J Peffers; Katie Lee; Luis M Rubio-Martinez
Journal:  BMC Vet Res       Date:  2018-03-20       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.